FOXO4-DRI: Research Overview and Mechanism
FOXO4-DRI is a D-retro-inverso interfering peptide studied in laboratory and preclinical research within cellular-senescence and senolytics models, where it is investigated for disrupting the FOXO4-p53 protein interaction. Because its exact construct varies by supplier, its sequence and molecular weight should be reconciled against the Certificate of Analysis. It is supplied as a lyophilized powder for research use only and is not approved for human use, and this overview describes what it is studied for in research literature, not a therapeutic effect.
What FOXO4-DRI is
FOXO4-DRI is a large interfering peptide (the C228H388N86O64 form is near 5358 g/mol) built in the D-retro-inverso configuration, meaning it uses D-amino acids arranged on a reversed backbone. This design is studied for improved resistance to enzymatic degradation relative to a conventional L-peptide, while preserving the spatial arrangement of side chains that governs binding.
Constructs supplied under this name vary: some include a poly-arginine cell-penetrating tag and others a shorter fragment, which changes the sequence, formula, and mass. For that reason the exact molecular details must be reconciled against the lot Certificate of Analysis.
Pathways it is studied within
In research models, FOXO4-DRI is studied within cellular senescence and senolytics. Its investigated mechanism is competitive disruption of the protein-protein interaction between the transcription factor FOXO4 and the tumor-suppressor p53, which is studied for releasing p53 from sequestration and, in senescent cells, influencing their viability. This places it within p53-signaling and protein-protein-interaction research.
In preclinical senolytics research reported in the aging-biology literature, the peptide has been examined in aged and progeroid mouse models rather than in humans. That work is described here in the third person as published research, not as a therapeutic claim, and no FOXO4-DRI construct is an approved drug.
Handling and documentation
Pinnacle FOXO4-DRI ships as a lyophilized powder with a lot-matched Certificate of Analysis. This is a large, arginine-rich construct: the value quoted on this page is near 5358 g/mol for the C228H388N86O64 form, but because vendors differ in whether they include the full poly-arginine cell-penetrating tag or a shorter fragment, the sequence, formula, and mass printed on the lot certificate are the only values to calculate from.
Arginine-rich peptides are strongly hygroscopic, so keep the sealed vial at -20C and shielded from light, let it warm to room temperature before opening to limit condensation, reconstitute in bacteriostatic water, and refrigerate the solution while minimizing freeze-thaw cycles. Reconcile CAS 2460055-10-9 against the COA.
All products are intended strictly for in-vitro laboratory research and development use only. Not for human or veterinary use, not a drug, food, or cosmetic, and not intended to diagnose, treat, cure, or prevent any disease.